This brand name is authorized in Austria, France, Poland, Spain.
The drug ERAZABAN contains one active pharmaceutical ingredient (API):
1
|
UNII
9G1OE216XY - DOCOSANOL
|
|
The exact mechanism of the antiviral activity of docosanol is unknown. In vitro studies indicate that docosanol affects the fusion between the virus and the plasma membrane, which inhibits intracellular uptake and replication of virus. Docosanol has no effect against non-enveloped viruses. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| D06BB11 | Docosanol | D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BB Antivirals |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| ES | Centro de información online de medicamentos de la AEMPS | 79372 |
| FR | Base de données publique des médicaments | 66326694 |
| PL | Rejestru Produktów Leczniczych | 100176440 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.